Study background: Chemerin is one of the recently discovered adipocytokines, a chemoattractant protein consisting of 131 to 137 amino acids expressing mostly in adipocytes. Chemerin affects adipogenesis and glucose homeostasis, have a direct or indirect impact on the inflammatory response. International scientific literature studies the relationship between chemerin and diabetes, obesity and metabolic syndrome markers.
Methods: The study included 159 clinically asymptomatic patients (age 30-45) with an average age of 37.3 ± 4.0 years, in total 79 women. The following anthropometric measurements and biochemical parameters were measured: weight, height, BMI and fasting glucose, insulin, glycated hemoglobin, total cholesterol with its fractions, liver enzymes and immunological marker-serum chemerin. All patients underwent a CT examination of the liver with multilayer spiral computer tomograph. The density of the liver and spleen, liver index and liver/spleen index was determined.
Results: Increased BMI correlates with an increased chemerin level, HOMA-IR value and TG level. A chemerin level raise also elevates the ALT and GGT blood levels, as well as the mean liver density among all three groups. The liver index and the liver/spleen index is greater in the normal weight group compared with the overweight and obese groups. HOMA-IR has a medium close-correlation with the chemerin level in the total group and overweight group. CTderived liver indicators (mean liver density, liver index, liver/ spleen index) have a statistically significant but weak correlation with chemerin level both in the total group and overweight group.
Conclusion: Chemerin is adipokine, which has a significant, but not yet unambiguous role in the metabolic process. Chemerin correlation with almost all MS criteria show that even asymptomatic patients should pay attention even if only one MS criterion is increased, focusing on checking other criteria.